首页>投融资
Oxford Nanopore Technologies
上市后再融资
Oxford Nanopore Technologies Ltd develops nanopore-based electronic systems for analyzing single molecules, including DNA, RNA, and proteins.In January 2023, Oxford Nanopore Technologies Ltd issued 384,471 ordinary shares of £0.0001 each under the company's share option plans and the issuance of shares under certain of the company's remuneration schemes.In January 2022, Oxford Nanopore Technologies Ltd expected to report core Life Science Research Tools (LSRT) of above £120 million, compared to LSRT revenue of £65.5 million in FY20, representing an annual growth in excess of 83%. The company expected to report total revenue of above £126 million, compared to the total revenue of £113.9 million in FY20
基本信息
-
公司全称Oxford Nanopore Technologies Ltd
-
类型DNA测序产品研发商
-
产业领域试剂/耗材、器械/设备、检测服务
-
公司人数101~500人
-
地址Gosling Building,Oxford Science Park Edmund Halley Road OXFORD OX4; GB; Telephone: +448450347900; Fax: +448450347901;
-
联系电话440845 034 7900
-
邮箱info@nanoporetech.com
-
成立时间2005-01-01
投融资
-
2024-07-31上市后再融资5000万英镑诺和诺德
-
2023-10-19上市后再融资7000万英镑BioMerieux
-
2021-10-11上市未透露未透露
-
2021-05-06E~PreIPO1.95亿英镑IP Group PlcNikonWellington ManagementM&G Investments
-
2020-11-09未透露8440万英镑普华资本
-
2020-10-13E~PreIPO8440万英镑未透露
-
2020-05-26未透露4840万英镑未透露
-
2020-01-02未透露1.09亿欧元未透露
-
2018-10-18未透露6600万美元Amgen
-
2018-03-20未透露1亿英镑GIC/新加坡政府投资公司Hostplus建银国际
-
2016-12-12未透露1亿英镑GT HealthcareWoodford Investment ManagementIP Group Plc
-
2015-07-20未透露7000万英镑IP Group Plc
-
2014-08-12未透露3500万英镑Woodford Investment ManagementIP Group Plc
-
2013-11-15捐赠/众筹5640万英镑未透露
-
2013-10-09未透露4000万英镑Odey Asset Management
-
2012-05-03未公开3140万英镑IP Group PlcLansdowne PartnersInvesco Private Capital
-
2011-04-26未公开2500万英镑IP Group PlcLansdowne PartnersInvesco Private Capital
-
2010-02-01C轮1740万英镑IP Group PlcLansdowne PartnersInvesco Private CapitalIllumina
- 加载更多
相关投融资企业
上市后再融资
Oxford Nanopore Technologies Ltd develops nanopore-based electronic systems for analyzing single molecules, including DNA, RNA, and proteins.In January 2023, Oxford Nanopore Technologies Ltd issued 384,471 ordinary shares of £0.0001 each under the company's share option plans and the issuance of shares under certain of the company's remuneration schemes.In January 2022, Oxford Nanopore Technologies Ltd expected to report core Life Science Research Tools (LSRT) of above £120 million, compared to LSRT revenue of £65.5 million in FY20, representing an annual growth in excess of 83%. The company expected to report total revenue of above £126 million, compared to the total revenue of £113.9 million in FY20
上市后再融资
Oxford Nanopore Technologies Ltd develops nanopore-based electronic systems for analyzing single molecules, including DNA, RNA, and proteins.In January 2023, Oxford Nanopore Technologies Ltd issued 384,471 ordinary shares of £0.0001 each under the company's share option plans and the issuance of shares under certain of the company's remuneration schemes.In January 2022, Oxford Nanopore Technologies Ltd expected to report core Life Science Research Tools (LSRT) of above £120 million, compared to LSRT revenue of £65.5 million in FY20, representing an annual growth in excess of 83%. The company expected to report total revenue of above £126 million, compared to the total revenue of £113.9 million in FY20
上市
Oxford Nanopore Technologies Ltd develops nanopore-based electronic systems for analyzing single molecules, including DNA, RNA, and proteins.In January 2023, Oxford Nanopore Technologies Ltd issued 384,471 ordinary shares of £0.0001 each under the company's share option plans and the issuance of shares under certain of the company's remuneration schemes.In January 2022, Oxford Nanopore Technologies Ltd expected to report core Life Science Research Tools (LSRT) of above £120 million, compared to LSRT revenue of £65.5 million in FY20, representing an annual growth in excess of 83%. The company expected to report total revenue of above £126 million, compared to the total revenue of £113.9 million in FY20
浙公网安备33011002015279
本网站未发布麻醉药品、精神药品、医疗用毒性药品、放射性药品、戒毒药品和医疗机构制剂的产品信息